• When a clinician diagnoses a

  2024-04-25

  

  When a clinician diagnoses a person with AD, the person is transformed into a patient with the disease. The person is a member of a patient group associated with behaviors, abilities, and experiences related both formally and informally to the diagnosis [10]. The diagnostic label implies what signs

• br Acknowledgements Dr Paul J Gasser is supported by the

  2024-04-25

  

  Acknowledgements Dr. Paul J. Gasser is supported by the National Institutes of Health (grant number R01DA032895), and the Charles E. Kubly Mental Health Research Center. Dr. Christopher A. Lowry is supported by the National Institutes of Health (grant number R21 MH116263), the Department of the N

• An alternative approach to the administration of ADO agonist

  2024-04-25

  

  An alternative approach to the administration of ADO agonists is to amplify the actions of endogenous ADO by inhibiting the ADO-metabolizing enzyme, ADO kinase (AK). Inhibition of AK has the net effect of potentiating the local concentration and the effects of ADO in the extracellular compartment. T

• Furthermore our lab previously reported that cadmium treatme

  2024-04-25

  

  Furthermore, our lab previously reported that cadmium treatment increased AChE-S and decreased AChE-R variants gene expression, which mediates the cell death observed on basal forebrain cholinergic neurons (Del Pino et al., 2016b). AChE-R decreased expression, which presents a neuroprotective role i

• At present drugs that specifically inhibit YAP activity are

  2024-04-25

  

  At present, drugs that specifically inhibit YAP activity are not available. In fact, verteporfin, which was originally described as a specific inhibitor of YAP-TEAD interaction, has been recently shown to exert its activity through selective induction of proteotoxicity rather than through YAP inhibi

• The take home message here

  2024-04-25

  

  The take-home message here is that, although Aurora A phosphorylated on T288 is the activated isoform of Aurora A, measuring the level of phosphorylation of T288 does not reflect Aurora A kinase activity (Figure 5). What would be the most appropriate readout for an in vivo Aurora A kinase activity

• This evidence suggests the strong clinical relevance

  2024-04-24

  

  This evidence suggests the strong clinical relevance of the identification of acquired resistance mechanisms for a proper therapeutic decision in patients with ALK-rearranged NSCLC. When the tissue is not available, the analysis of circulating tumor DNA (cfDNA) can be a valid alternative for the det

• In our previous study we

  2024-04-24

  

  In our previous study we found that the total activity of aldehyde dehydrogenase in cancer histamine-1 receptor antagonist of RCC is at the same level as in normal renal tissue [10]. These findings are similar to our results in serum patients with renal cancer. There is no significant difference bet

• Analyses of brain CSCs isolated from pediatric

  2024-04-24

  

  Analyses of histamine receptors CSCs isolated from 24 pediatric and six adult brain tumors detected ALDH levels proportional to tumor type and aggressiveness. ALDH-expressing cells (ALDH+) formed spheroids while ALDH1 pharmacological inhibition by a combination of DEAB and RA decreased significantl

• This study revealed that EAAT expression was increased

  2024-04-24

  

  This study revealed that EAAT2 HBTU was increased 4–8 weeks after cauterization as our previous work (Park et al., 2009). RGC death could not be blocked despite activation of EAAT2, which is one of glutamate transporters in cone photoreceptors and some bipolar cells, in chronic ocular hypertension

• br Conflict of Interest br Transparency Document br Introduc

  2024-04-24

  

  Conflict of Interest Transparency Document Introduction Mitoxantrone (MXT) is an androstenedione chemotherapeutic agent that is used to treat acute nonlymphocytic leukemia, acute lymphoblastic leukemia, prostate cancer, metastatic breast cancer, and non-Hodgkin’s lymphoma [13], [14]. It is

• Given the powerful and ubiquitous nature of adenosine action

  2024-04-24

  

  Given the powerful and ubiquitous nature of adenosine action within the CNS, basal levels of extracellular adenosine are carefully regulated and are estimated to be in the region of 30–300 nM (Fredholm et al., 2001). The two main pathways for the control of extracellular adenosine involve phosphoryl

• br Conflict of interest br

  2024-04-24

  

  Conflict of interest Financial support Acknowledgments This work was supported by the Japanese Millennium project. We thank all members of the Center for Genomic Medicine of RIKEN and Dainippon-Sumitomo Pharma Co., Ltd. for supporting this study. We are also grateful to members of the Hiros

• In an attempt to complete the overview of resistance mechani

  2024-04-24

  

  In an attempt to complete the overview of resistance mechanisms in Spanish codling moth populations, the aims of the present work were to assess the actual occurrence of AChE and kdr mutations in codling moth field populations from different pome fruit-growing areas of Spain, concurrently with the f

• Hypoxia induced replication arrest has been demonstrated

  2024-04-23

  

  Hypoxia-induced replication arrest has been demonstrated in a variety of organisms in addition to mammals; including Zebrafish , , and (brine shrimp) which have been shown to survive for 4 years and longer in anoxic conditions . Despite this breadth of study, little is known about the mechanism of

15567 records 166/1038 page Previous Next First page 上5页 166167168169170 下5页 Last page